Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 1073

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9C
Chunk 1073
---
16  
     —  
     — 
  
    Outstanding at December
    31, 2024 
     304,125  
    $6.95  
     4.20  
    $— 

    Vested and exercisable
    at December 31, 2024 
     304,125  
    $6.95  
     4.20  
    $— 

As
of December 31, 2024, there was no unrecognized compensation cost related to non-vested stock options.

During the year ended December 31, 2024, 208,031 options were exercised at an exercise price of $1.155, of which 143,183 options were from a cashless exercise, and 137,854 options were forfeited due to a cashless exercise.

    F-14

Restricted
Stock Awards

The
following table summarizes restricted stock award activity under the 2014 and 2024 Plan:

SUMMARY OF RESTRICTED STOCK AWARD

    As of December 31, 2024 

    Number
    of restricted stock awards (RSA)  
    Weighted-
    average grant price  
    FMV
    on grant date  
    Vested
    number of RSA  
    Unvested
    number of RSA 
  
    Balance at December 31, 2023 
     540,969  
    $2.24  
    $1,209,400  
     462,298  
     78,671 
  
    Granted 
     865,423  
     1.81  
     1,570,834  
     517,941  
     347,482 
  
    Forfeited 
     (77,096) 
     1.80  
     (139,173) 
     —  
     (77,096)
  
    Balance at December 31, 2024 
     1,329,296  
    $2.24  
    $2,641,061  
     980,239  
     349,057 

During
the year ended December 31, 2024, the Company issued restricted stock awards (“RSAs”) for 865,423 shares of Common Stock to employees,
non-employees, and the Board of Directors. The shares